Benfotiamine

DB11748ApprovedInvestigationalWithdrawnSmall molecule

Benfotiamine is a derivative of thiamine thought to be useful in the management of diabetic neuropathy, although evidence is lacking. Benfotiamine has been investigated for the treatment and prevention of Diabetic Nephropathy and Diabetes Mellitus, Type 2.

Chemical structure of Benfotiamine
Mechanism
Curator reviewed
Formula / weight
C19H23N4O6PS · 466.45 g/mol (avg)
Also known as
Benphothiamine · Benzoylthiamine monophosphate · S-benzoylthiamine monophosphate
Code names
8088-CB

Resolves to

Compound
UNIIY92OUS2H9BCAS22457-89-2ChEMBLCHEMBL4303665ChEBI41039PubChem3032771
Clinical / RWD
RxNorm18891ATCA11DA03
Structure
InChIKeyBTNNPSLJPBRMLZ-LGMDPLHJSA-NSMILESC\C(N(CC1=CN=C(C)N=C1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)C1=CC=CC=C1
Targets
P29401TKTQ15391P2RY14

What you can answer from here — as of July 07, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
11Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
9Marketed productsAcross 3 countries and 5 labellers
Sign in
1ATC codeIncluding every combination product, plus 10 drug categories
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Benfotiamine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In